Thursday 27 October 2016

Astrazeneca to invest $285m in biologics facility in Sweden

Published 18/05/2015 | 09:28

British drugmaker AstraZeneca
British drugmaker AstraZeneca

Astrazeneca is to invest $285m at a biologics manufacturing facility in Södertälje, Sweden.

  • Go To

The investment is the first phase of a potential three-part programme to expand Astrazeneca's biologics manufacturing capabilities

Subject to relevant approvals by local authorities, the plant will create between 150 and 250 highly skilled new roles at Astrazeneca by 2019.


Read More

Promoted articles

Editors Choice

Also in Business